Abstract：
:The annual cost of managing migraine totals billions of US dollars. This retrospective economic analysis of a clinical trial comparing subcutaneous dihydroergotamine mesylate (DHE) with subcutaneous sumatriptan in the treatment of acute migraine is appropriate because, although each product has been shown to be efficacious, the acquisition cost of sumatriptan is over 3 times that of DHE. Total costs in each treatment group were calculated and applied independently to 11 clinical trial efficacy measures. Three of the efficacy measures showed no statistically significant difference between treatment arms, leading to a decision to use the less expensive DHE. In 4 of the efficacy measures. DHE was the obvious choice because it is more efficacious and less expensive. For the final 4 efficacy measures, where sumatriptan is more efficacious and more expensive, incremental cost-efficacy ratios were calculated to determine the additional expenditure required to achieve outcomes associated with quick relief. Depending on the efficacy variable chosen and the assumptions used in the model, the incremental cost-efficacy ratios ranged from $US4000 to $US6700 per year (1993 dollars) for each additional patient who is successfully treated with sumatriptan compared with DHE. Therefore, in a population of 100 migraineurs, an additional 13 to 22 patients would achieve these short term benefits of sumatriptan, although it would cost an additional $US88 395 annually, given the assumptions made. Because each product has unique advantages, we conclude that the more cost-efficacious product is dependent on the outcome of interest and the amount that the patient or provider is willing to pay to achieve that outcome.
journal_name
Pharmacoeconomicsjournal_title
PharmacoEconomicsauthors
Payne K,Kozma CM,Lawrence BJdoi
10.2165/00019053-199610010-00006subject
Has Abstractpub_date
1996-07-01 00:00:00pages
59-71issue
1eissn
1170-7690issn
1179-2027journal_volume
10pub_type
临床试验,杂志文章,随机对照试验abstract：:The National Institute for Health and Care Excellence (NICE) invited Pfizer, the manufacturer of inotuzumab ozogamicin (henceforth inotuzumab), to submit clinical- and cost-effectiveness evidence for inotuzumab as part of NICE's single technology appraisal process. The Centre for Reviews and Dissemination and the Cent...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-019-00779-4
更新日期：2019-09-01 00:00:00
abstract：BACKGROUND:Combination therapies with cetuximab (Erbitux®; Merck Serono UK Ltd) and panitumumab (Vectibix®; Amgen UK Ltd) are shown to be less effective in adults with metastatic colorectal cancer who have mutations in exons 2, 3 and 4 of KRAS and NRAS oncogenes from the rat sarcoma (RAS) family. OBJECTIVE:The objecti...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-018-0630-9
更新日期：2018-07-01 00:00:00
abstract：BACKGROUND:In the Netherlands, decisions about the reimbursement of new pharmaceuticals are based on cost effectiveness, as well as therapeutic value and budget impact. Since 1 January 2005, drug manufacturers are formally required to substantiate the cost effectiveness of drugs that have therapeutic added value in com...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/11539850-000000000-00000
更新日期：2012-03-01 00:00:00
abstract：:Decision-analytic models play a key role in informing healthcare resource allocation decisions. However, there are ongoing concerns with the credibility of models. Modelling methods guidance can encourage good practice within model development, but its value is dependent on its ability to address the areas that modell...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-017-0499-z
更新日期：2017-06-01 00:00:00
abstract：:Community-acquired pneumonia (CAP) is a common diagnosis and care of CAP is responsible for significant healthcare expenditures, the majority of which are for patients who require hospitalisation. Studies have shown that significant variation exists among institutions with respect to antibacterial costs and length of ...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-200422070-00001
更新日期：2004-01-01 00:00:00
abstract：:External genital warts (EGW) are a sexually transmitted infection caused by various strains of human papillomavirus (HPV). Several studies have described the direct and indirect costs of EGW, while others have reported on the burden of EGW in terms of the impact on the quality of life (QOL) of patients. The arrival of...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/11591170-000000000-00000
更新日期：2012-01-01 00:00:00
abstract：BACKGROUND:The apparent decrease in the rate of approval of new molecular entities has provoked extensive discussion and fears that the productivity of biopharmaceutical research and development has severely declined in recent years. OBJECTIVE:To investigate the extent to which traditional measures of innovative outpu...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-200624002-00008
更新日期：2006-12-01 00:00:00
abstract：:For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals' willingness to pay (WTP) or quality-adjusted life-years (QALYs) have to be estimated at an aggregate level. So far, aggregation has usually been don...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-200119040-00001
更新日期：2001-01-01 00:00:00
abstract：:Potential conflict between the goals of the investigators and the sponsors of pharmacoeconomic and clinical research has been well documented. Although there have been efforts to formalise relationships between sponsors and investigators in some areas of clinical research, no set of guidelines or standardised contract...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-199507030-00004
更新日期：1995-03-01 00:00:00
abstract：:Lung cancer remains the leading cause of cancer-related death and economic burden worldwide. Despite the heavy toll of lung cancer, multiple new advances have improved patient outcomes, largely through precision medicine and targeted therapy. The associated rising economic burden however may impact the uptake of novel...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-017-0563-8
更新日期：2017-12-01 00:00:00
abstract：BACKGROUND:There are few empirical studies on the valuation of health profiles that describe the short-term fluctuations of chronic diseases. OBJECTIVE:This study aimed to value chronic obstructive pulmonary disease (COPD) health profiles, which describe the health of these patients over the course of 1 year from a so...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-200927060-00003
更新日期：2009-01-01 00:00:00
abstract：BACKGROUND:Low-dose aspirin (ASA) is effective for secondary prevention of ischemic stroke but can increase the risks of hemorrhagic stroke, upper gastrointestinal bleeding (UGIB), and dyspepsia. Prophylactic administration of proton pump inhibitors (PPIs) reduces the risks of these digestive symptoms. We investigated ...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-015-0289-4
更新日期：2015-10-01 00:00:00
abstract：:The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering-Plough/Centocor) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have responded inadequately to ...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/11595920-000000000-00000
更新日期：2012-04-01 00:00:00
abstract：:Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is ...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-199712040-00002
更新日期：1997-10-01 00:00:00
abstract：:The application of cost-effectiveness methodology is particularly important in widespread diseases such as hypertension. However, because prospective cost-effectiveness analyses comparing different antihypertensive drugs are not currently available, differences in the cost effectiveness of these drugs can only be esti...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-199508060-00006
更新日期：1995-12-01 00:00:00
abstract：OBJECTIVE:To explore whether the National Institute for Health and Clinical Excellence (NICE) takes account of concerns other than just incremental cost effectiveness in commissioning healthcare services. METHOD:A stated preference binary choice experiment was used to explore the preferences of members of NICE's Appra...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-200725080-00006
更新日期：2007-01-01 00:00:00
abstract：:In this paper we consider the evolving American healthcare landscape and what it means for the use of economic evaluation of health interventions. We emphasise that use of economic evaluation in the US is unlikely to follow the European, Canadian or Australian models, which use cost effectiveness openly and explicitly...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-200624110-00012
更新日期：2006-01-01 00:00:00
abstract：:As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of vedolizumab (Takeda UK) to submit evidence of the clinical effectiveness and cost effectiveness of vedolizumab for the treatment of patients with moderate-to-severe active ...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-015-0334-3
更新日期：2016-03-01 00:00:00
abstract：:Economic analysts are increasingly likely to rely on systematic reviews and meta-analyses of health state utility values to inform the parameter inputs of decision-analytic modelling-based economic evaluations. Beyond the context of economic evaluation, evidence from systematic reviews and meta-analyses of health stat...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-018-0670-1
更新日期：2018-09-01 00:00:00
abstract：BACKGROUND:Probabilistic sensitivity analysis (PSA) in cost-effectiveness analysis involves sampling a large number of realisations of an economic model. For some parameters, we may be uncertain around the true mean values of the variables, but the ordering of the values is known. Typical sampling approaches lack eithe...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-017-0584-3
更新日期：2018-03-01 00:00:00
abstract：OBJECTIVE:To develop incidence-based estimates of the cost of several diabetes-related complications. DESIGN AND SETTING:This was a retrospective cohort study in a large health maintenance organisation. A total of 8905 patients with type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus and 36...
journal_title：PharmacoEconomics
pub_type： 临床试验,杂志文章
doi：10.2165/00019053-199916030-00005
更新日期：1999-09-01 00:00:00
abstract：:As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Sanofi Genzyme) of sarilumab (SAR; Kevzara®) to submit evidence of its clinical effectiveness and cost-effectiveness for previously treated moderate or severe rheumatoid arth...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.1007/s40273-018-0677-7
更新日期：2018-12-01 00:00:00
abstract：BACKGROUND:Potential differences in toxicity, potency and acquisition price among the liposomal amphotericin B formulations makes it unclear which agent is less costly when total resource consumption and treatment-associated costs are considered. DESIGN:A retrospective cost-minimisation analysis in 51 patients was per...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-200422050-00004
更新日期：2004-01-01 00:00:00
abstract：:This article examines the twin concepts of the statistical significance and quantitative importance of observed differences in studies comparing medicines in terms of economic parameters such as cost-effectiveness and measures of health-related quality of life (HRQOL). Central to the design and interpretation of any ...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/00019053-199405050-00005
更新日期：1994-05-01 00:00:00
abstract：OBJECTIVE:To evaluate the cost effectiveness of dabrafenib versus dacarbazine and vemurafenib as first-line treatments in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma from a Canadian healthcare system perspective. METHODS:A partitioned-survival analysis model with three mutually exclus...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-014-0241-z
更新日期：2015-04-01 00:00:00
abstract：:To review and critically evaluate published cost-utility analyses (CUAs) pertaining to pharmaceuticals for the past 3 decades. We examined data from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), which contains detailed information on English-language CUAs and their ratios (in $US...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/11312720-000000000-00000
更新日期：2009-01-01 00:00:00
abstract：:Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy in patients with LGS uncontrolled on one to t...
journal_title：PharmacoEconomics
pub_type： 杂志文章,评审
doi：10.2165/11208630-000000000-00000
更新日期：2012-03-01 00:00:00
abstract：BACKGROUND:The COUGAR-02 trial recently showed survival and quality-of-life benefits of docetaxel and active symptom control (DXL + ASC) over active symptom control (ASC) alone in patients with refractory oesophagogastric adenocarcinoma. AIM:The aim of this study was to conduct an economic evaluation conforming to Nat...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-015-0324-5
更新日期：2016-01-01 00:00:00
abstract：:The regulation of pricing and trade for in-patent medicines within the European pharmaceutical sector presents a major challenge. In conditions of large sunk costs and consumers with differential willingness to pay--between different Member States--an efficient way of pricing in-patent medicines is through price discr...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.2165/00019053-200018001-00008
更新日期：2000-01-01 00:00:00
abstract：BACKGROUND:Lung cancer is among the top causes of cancer-related deaths. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors can increase progression-free survival compared with standard chemotherapy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). OBJECTIVE:The aim o...
journal_title：PharmacoEconomics
pub_type： 杂志文章
doi：10.1007/s40273-015-0305-8
更新日期：2015-11-01 00:00:00
